Systemic Treatment Algorithm for Renal Cell Cancer

ADJUVANT THERAPY

No standard treatment, consider entry into clinical trial

LOCALLY ADVANCED / RECURRENT DISEASE

Treat as metastatic disease or consider metastatectomy



- Consider funding arrangements before prescribing
- Recruitment to clinical trials should be considered where appropriate

| Version | Prepared by | Approved by Consultant Oncologist | Date approved | Changes from previous version |
|---------|--------------------|--------------------------------------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| 3.0 | Victoria Taylor | Dr Omi Parikh | May 2019 | Addition of Nivolumab & Ipilimumab first line. Removal of Tivozanib compassionate use scheme. |